Correlates of pancreatic enzyme replacement therapy intake in adults with cystic fibrosis: Results of a cross-sectional study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Correlates of pancreatic enzyme replacement therapy intake in adults with cystic fibrosis: Results of a cross-sectional study. / Olsen, Mette Frahm; Kjøller-Svarre, Maria; Møller, Grith; Katzenstein, Terese Lea; Nielsen, Bibi Uhre; Pressler, Tacjana; Lewis, Jack Ivor; Mathiesen, Inger H; Mølgaard, Christian; Faurholt-Jepsen, Daniel.
In: Nutrients, Vol. 14, No. 7, 1330, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Correlates of pancreatic enzyme replacement therapy intake in adults with cystic fibrosis: Results of a cross-sectional study
AU - Olsen, Mette Frahm
AU - Kjøller-Svarre, Maria
AU - Møller, Grith
AU - Katzenstein, Terese Lea
AU - Nielsen, Bibi Uhre
AU - Pressler, Tacjana
AU - Lewis, Jack Ivor
AU - Mathiesen, Inger H
AU - Mølgaard, Christian
AU - Faurholt-Jepsen, Daniel
N1 - CURIS 2022 NEXS 088
PY - 2022
Y1 - 2022
N2 - Most people with cystic fibrosis (pwCF) develop pancreatic insufficiency and are treated with pancreatic enzyme replacement therapy (PERT). We aimed to describe the use of PERT and assess the correlates of PERT dose in adult pwCF. In a cross-sectional study at the Copenhagen CF Centre, the participants reported PERT intake, gastrointestinal (GI) symptoms and the use of concomitant treatments. Demographic and clinical characteristics were extracted from the Danish CF Registry. We used linear regression to assess the correlates of PERT dose per kg bodyweight (U-lipase/kg). We included 120 pwCF with a median age of 32.9 years, 46% women and 72% F508delta homozygote. The PERT dose ranged from 0 to 6160 U-lipase/kg per main meal (mean 1828; SD 1115). The PERT dose was associated with participants’ sex (men vs. women: 661; 95% CI: 302; 1020 U-lipase/kg), age (−16; 95% CI: −31; −1 U-lipase/kg per year) and weight (−45; 95% CI: −58; −31 U-lipase/kg per kg). Having less frequent constipation and being lung transplanted were also associated with a higher PERT dose. A third of participants did not take PERT for snacks, and this was associated with the frequency of diarrhoea. These findings indicate that PERT intake may be improved to reduce GI symptoms.
AB - Most people with cystic fibrosis (pwCF) develop pancreatic insufficiency and are treated with pancreatic enzyme replacement therapy (PERT). We aimed to describe the use of PERT and assess the correlates of PERT dose in adult pwCF. In a cross-sectional study at the Copenhagen CF Centre, the participants reported PERT intake, gastrointestinal (GI) symptoms and the use of concomitant treatments. Demographic and clinical characteristics were extracted from the Danish CF Registry. We used linear regression to assess the correlates of PERT dose per kg bodyweight (U-lipase/kg). We included 120 pwCF with a median age of 32.9 years, 46% women and 72% F508delta homozygote. The PERT dose ranged from 0 to 6160 U-lipase/kg per main meal (mean 1828; SD 1115). The PERT dose was associated with participants’ sex (men vs. women: 661; 95% CI: 302; 1020 U-lipase/kg), age (−16; 95% CI: −31; −1 U-lipase/kg per year) and weight (−45; 95% CI: −58; −31 U-lipase/kg per kg). Having less frequent constipation and being lung transplanted were also associated with a higher PERT dose. A third of participants did not take PERT for snacks, and this was associated with the frequency of diarrhoea. These findings indicate that PERT intake may be improved to reduce GI symptoms.
KW - Faculty of Science
KW - Cystic fibrosis
KW - Gastrointestinal symptoms
KW - Pancreatic enzyme replacement therapy
KW - Pancreatic insufficiency
U2 - 10.3390/nu14071330
DO - 10.3390/nu14071330
M3 - Journal article
C2 - 35405943
VL - 14
JO - Nutrients
JF - Nutrients
SN - 2072-6643
IS - 7
M1 - 1330
ER -
ID: 300992030